http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Mei Uemura,Yutaka Yano,Toshinari Suzuki,Taro Yasuma,Toshiyuki Sato,Aya Morimoto,Samiko Hosoya,Chihiro Suminaka,Hiromu Nakajima,Esteban C. Gabazza,Yoshiyuki Takei 대한당뇨병학회 2017 Diabetes and Metabolism Journal Vol.41 No.4
patients and institutions. We are developing a glucose area under the curve (AUC) monitoring system without blood sampling using a minimally invasive interstitial fluid extraction technology (MIET). Here we evaluated the accuracy of interstitial fluid glucose (IG) AUC measured by MIET in patients with diabetes for an extended time interval and the potency of detecting hyperglycemia using CGM data as a reference. Methods: Thirty-eight inpatients with diabetes undergoing CGM were enrolled. MIET comprised a pretreatment step using a plastic microneedle array and glucose accumulation step with a hydrogel patch, which was placed on two sites from 9:00 AM to 5:00 PM or from 10:00 PM to 6:00 AM. IG AUC was calculated by accumulated glucose extracted by hydrogel patches using sodium ion as standard. Results: A significant correlation was observed between the predicted AUC by MIET and CGM in daytime (r=0.76) and nighttime (r=0.82). The optimal cutoff for the IG AUC value of MIET to predict hyperglycemia over 200 mg/dL measured by CGM for 8 hours was 1,067.3 mg·hr/dL with 88.2% sensitivity and 81.5% specificity. Conclusion: We showed that 8-hour IG AUC levels using MIET were valuable in estimating the blood glucose AUC without blood sampling. The results also supported the concept of using this technique for evaluating glucose excursion and for screening hyperglycemia during 8 hours in patients with diabetes at any time of day.
( Akihiro Koga ),( Toshiyuki Matsui ),( Noritaka Takatsu ),( Yasumichi Takada ),( Masahiro Kishi ),( Yutaka Yano ),( Takahiro Beppu ),( Yoichiro Ono ),( Kazeo Ninomiya ),( Fumihito Hirai ),( Takashi N 대한장연구학회 2018 Intestinal Research Vol.16 No.2
Background/Aims: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn’s disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could become a predictor of mucosal healing (MH) (Study 2). Methods: Study 1 was conducted in 108 patients, including those with LOR and remission to compare ATI and TLI in discriminating the 2 conditions based on receiver operating characteristic (ROC) curve analyses. Study 2 involved 35 patients who were evaluated endoscopically. Results: In Study 1, there were no differences between the 2 assays in ROC curve analyses; the TLI cutoff value for LOR was 2.6 μg/mL (sensitivity, 70.9%; specificity, 79.2%), and the ATI cutoff value was 4.9 μg/mL (sensitivity, 65.5%; specificity, 67.9%). The AUROC (area under the ROC curve) of TLI was greater than that of ATI. AUROC was useful for discriminating between the 2 conditions. In Study 2, the TLI was significantly higher in the colonic MH group than in the non-MH group (2.7 μg/mL vs. 0.5 μg/mL, P=0.032). Conclusions: TLI is better than ATI for clinically diagnosing LOR, and a correlation was observed between TLI and colonic MH. (Intest Res 2018;16:223-232)
Amelioration of Atherosclerosis by the New Medicinal Mushroom Grifola gargal Singer
Etsuko Harada,Corina N. D’Alessandro-Gabazza,Masaaki Toda,Toshihiro Morizono,Ayshwarya-Lakshmi Chelakkot-Govindalayathil,Ziaurahman Roeen,Masahito Urawa,Taro Yasuma,Yutaka Yano,Toshimitsu Sumiya,Esteb 한국식품영양과학회 2015 Journal of medicinal food Vol.18 No.8
The beneficial effects of edible mushrooms for improving chronic intractable diseases have been documented. However, the antiatherogenic activity of the new medicinal mushroom Grifola gargal is unknown. Therefore, we evaluated whether Grifola gargal can prevent or delay the progression of atherosclerosis. Atherosclerosis was induced in ApoE lipoprotein-deficient mice by subcutaneous infusion of angiotensin II. Grifola gargal extract (GGE) was prepared and intraperitoneally injected. The weight of heart and vessels, dilatation/atheroma formation of thoracic and abdominal aorta, the percentage of peripheral granulocytes, and the blood concentration of MCP-1/CCL2 were significantly reduced in mice treated with GGE compared to untreated mice. By contrast, the percentage of regulatory T cells and the plasma concentration of SDF-1/CXCL12 were significantly increased in mice treated with the mushroom extract compared to untreated mice. In vitro, GGE significantly increased the secretion of SDF-1/CXCL12, VEGF, and TGF-β1 from fibroblasts compared to control. This study demonstrated for the first time that Grifola gargal therapy can enhance regulatory T cells and ameliorate atherosclerosis in mice.